

Implicit and explicit expectancies of cannabis use in patients with schizophrenia

Published: 10-11-2006

Last updated: 14-05-2024

This study will assess both implicit and explicit effect expectancies associated with marijuana in individuals with psychotic disorder. We will determine whether such expectancies are different from those of people in the general population. We will...

Ethical review	Approved WMO
Status	Pending
Health condition type	Other condition
Study type	Observational non invasive

Summary

ID

NL-OMON30151

Source

ToetsingOnline

Brief title

IEECS

Condition

- Other condition
- Schizophrenia and other psychotic disorders

Synonym

psychose, verslaving

Health condition

cannabis-verslaving/misbruik

Research involving

Human

Sponsors and support

Primary sponsor: Academisch Medisch Centrum

Source(s) of monetary or material Support: Zon-mw

Intervention

Keyword: cannabis, expectancies, IAT, schizophrenia

Outcome measures

Primary outcome

Explicit expectancies of cannabis use

Implicit expectancies of cannabis use

Difference of these expectancies between patients and healthy subjects.

Secondary outcome

Craving for cannabis.

Current and past use of cannabis and other drugs.

Study description

Background summary

A lot of patients with schizophrenia use cannabis. Cannabis use has an adverse impact on positive symptoms, compliance and prognosis. Patients say they use cannabis to enhance positive mood, and to cope with negative emotions.

To improve treatment for cannabis using schizophrenia patients, it is necessary to get more insight in their motivation and expectancies of cannabis use. These expectations can be measured in an explicit and implicit way.

Explicit expectations of cannabis use have been studied in the general populations as well as in patients with schizophrenia, with contradictory results. There are studies in which expectations between patients and controls do not differ, on the other hand there are studies in which the self-medication hypothesis is confirmed, therefore the results point out there is an 'extra' reason for patients to use cannabis, namely to alleviate their symptoms and side-effects of antipsychotics. Implicit expectations are expectations that

people are unaware of. Implicit expectations are measured in alcohol and drug research, but have never been tested in patients with schizophrenia.

Study objective

This study will assess both implicit and explicit effect expectancies associated with marijuana in individuals with psychotic disorder. We will determine whether such expectancies are different from those of people in the general population. We will determine whether the explicit expectancies are associated with personal drug use patterns, craving and implicit expectancies. Through this research we hope to develop more insight in cannabis related cognitions in patients with psychotic disorder. Most important we hope to get an answer to the question whether patients with psychotic disorder use cannabis as 'self-medication', to alleviate their symptoms or side-effects of anti-psychotic medication. A valid assessment of implicit and explicit expectancies of cannabis use will hopefully contribute in developing more insights in specific interventions for drug use disorder in patients with psychotic disorder. Knowledge of cannabis related cognitions in patients who never used cannabis, will also contribute in developing preventative measures, which is very important, because cannabis use has an adverse impact on the course and outcome of psychotic disorder.

Study design

It is a cross-sectional study design. Participants will be invited for one assesment in which two short interviews will be done, two questionnaires will be filled out and a computer task will be done. Participants are asked whether they may be invited for follow up 6 months after baseline for a short interview and a questionnaire they have to fill in.

Patients will be compared to healthy subjects.

It is expected that 200 participants will be included in this study.

Study burden and risks

There is no burden and risk associated with participation.

participants are seen once by a research assistant, for two short interviews, two questionnaires an a computer task. This takes one hour all together. Questions mainly focus on cannabis use and expectancies of cannabis use.

Participants are asked whether they can be assessed one more time after 6 months for two questionnaires on use of cannabis and craving for cannabis. This second assessment is done by one research assistant and takes 30 minutes.

Participants are of minor age as well as major age. In light of negative effects of cannabis use on course of schizophrenia it is of great importance to get insight into reasons for cannabis use in this population. Especially in

young patients
much health profit is expected of improved treatment.

Contacts

Public

Academisch Medisch Centrum

Tafelbergweg 25
1105 BC Amsterdam
Nederland

Scientific

Academisch Medisch Centrum

Tafelbergweg 25
1105 BC Amsterdam
Nederland

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adolescents (12-15 years)
Adolescents (16-17 years)
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Patients:

1. Age 16 - 40 years
 2. Command of the Dutch language
 3. Non-affective psychotic disorder; Controls
1. age 16- 40 years
 2. No family history of psychotic disorders

3. Command of the Dutch language
4. No psychosis in medical history

Exclusion criteria

Affective psychosis

Study design

Design

Study type:	Observational non invasive
Intervention model:	Other
Allocation:	Non-randomized controlled trial
Masking:	Open (masking not used)
Control:	Active
Primary purpose:	Basic science

Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	01-04-2006
Enrollment:	200
Type:	Anticipated

Ethics review

Approved WMO	
Application type:	First submission
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL11997.018.06